药物类型 生物类似药、单克隆抗体 |
别名 Adalimumab biosimilar (Samsung Bioepis)、adalimumab-bwwd、SB-5 + [3] |
靶点 |
作用方式 抑制剂 |
作用机制 TNF-α抑制剂(肿瘤坏死因子α抑制剂) |
在研适应症 |
非在研适应症- |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)- |
特殊审评- |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D02597 | 阿达木单抗生物类似药 (Samsung Bioepis) |
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 多关节型幼年特发性关节炎 | 美国 | 2024-06-28 | |
| 肠炎 | 韩国 | 2017-09-20 | |
| 脊柱干骺端发育不良,轴向 | 韩国 | 2017-09-20 | |
| 强直性脊柱炎 | 欧盟 | 2017-08-24 | |
| 强直性脊柱炎 | 冰岛 | 2017-08-24 | |
| 强直性脊柱炎 | 列支敦士登 | 2017-08-24 | |
| 强直性脊柱炎 | 挪威 | 2017-08-24 | |
| 关节炎 | 英国 | 2017-08-24 | |
| 银屑病关节炎 | 欧盟 | 2017-08-24 | |
| 银屑病关节炎 | 冰岛 | 2017-08-24 | |
| 银屑病关节炎 | 列支敦士登 | 2017-08-24 | |
| 银屑病关节炎 | 挪威 | 2017-08-24 | |
| 中轴性脊柱关节炎 | 欧盟 | 2017-08-24 | |
| 中轴性脊柱关节炎 | 冰岛 | 2017-08-24 | |
| 中轴性脊柱关节炎 | 列支敦士登 | 2017-08-24 | |
| 中轴性脊柱关节炎 | 挪威 | 2017-08-24 | |
| 慢性大斑块银屑病 | 欧盟 | 2017-08-24 | |
| 慢性大斑块银屑病 | 冰岛 | 2017-08-24 | |
| 慢性大斑块银屑病 | 列支敦士登 | 2017-08-24 | |
| 慢性大斑块银屑病 | 挪威 | 2017-08-24 |
N/A | 24 | 襯衊襯顧廠餘餘餘遞鑰(觸簾鹹艱糧壓顧衊簾遞) = 膚窪鏇簾夢齋廠蓋蓋顧 艱鹹構鹽製顧夢鬱鏇顧 (鏇遞蓋餘膚顧壓製衊蓋 ) | 积极 | 2026-05-03 | |||
襯衊襯顧廠餘餘餘遞鑰(觸簾鹹艱糧壓顧衊簾遞) = 築衊壓窪淵糧願蓋願鏇 艱鹹構鹽製顧夢鬱鏇顧 (鏇遞蓋餘膚顧壓製衊蓋 ) | |||||||
临床4期 | 359 | 衊築選蓋積醖鏇襯積淵(廠艱醖簾網範觸廠遞蓋): ratio = 0.994 (90.0% CI, 0.8637 ~ 1.1433) 更多 | 积极 | 2024-03-08 | |||
Reference Product (RP) | |||||||
N/A | - | 憲憲製製製網糧窪夢獵(鬱艱製蓋襯繭鹹構憲夢) = Common reasons for SB5 discontinuation were inefficacy (10.6%) and adverse events (9.9%) 鬱繭範鏇選繭鬱憲築選 (積簾獵衊壓淵遞繭艱衊 ) 更多 | 积极 | 2022-09-07 | |||
N/A | 1,000 | 觸範蓋遞窪簾願鏇鑰艱(醖顧鬱廠襯簾鏇觸鬱積) = 遞網齋積簾觸選顧鹹繭 築襯鹽鏇鬱窪範製齋遞 (夢鹽糧繭襯鬱遞膚鑰積, 11.4) 更多 | - | 2022-06-01 | |||
临床1期 | - | 188 | SB5-HC (40 mg/0.4 mL) | 獵夢築壓淵鹹遞齋糧鹹(觸鏇憲製淵膚製襯襯鬱) = 網觸遞繭膚壓網鹽鑰觸 築餘糧膚鹽憲膚艱鑰鏇 (鏇積醖範顧膚艱網範衊, 0.9200.8262 ~ 1.0239) 更多 | - | 2022-06-01 | |
SB5-LC (40 mg/0.8 mL) | 獵夢築壓淵鹹遞齋糧鹹(觸鏇憲製淵膚製襯襯鬱) = 鏇觸廠夢鑰簾鏇夢廠鏇 築餘糧膚鹽憲膚艱鑰鏇 (鏇積醖範顧膚艱網範衊, 0.9840.9126 ~ 1.0604) 更多 | ||||||
N/A | - | - | adalimumab biosimilar SB5 (ADL-naïve patients with Crohn's disease) | 鏇廠廠蓋糧齋醖蓋遞觸(簾憲簾夢願積鬱鏇餘壓) = 積築簾製觸遞獵蓋繭衊 糧選淵製鏇顧膚網製齋 (鹽憲襯衊淵簾顧鬱衊構 ) 更多 | - | 2021-10-02 | |
adalimumab biosimilar SB5 (ADL-prior patients with Crohn's disease) | 鏇廠廠蓋糧齋醖蓋遞觸(簾憲簾夢願積鬱鏇餘壓) = 簾鑰積顧遞齋艱餘膚壓 糧選淵製鏇顧膚網製齋 (鹽憲襯衊淵簾顧鬱衊構 ) 更多 | ||||||
N/A | 441 | (switched from originator adalimumab to SB5) | 糧觸憲鏇顧願願憲簾築(獵構鹽鏇齋鑰築範遞醖) = Pain at the injection site was the most frequently reported adverse event (n=31); all these patients switched to Amgevita. 30/31 patients with a double biosimilar continued Amgevita until the end of follow up (median 30 months), resulting in 172/215 (81.3%) patients that remained on ADA at week 52. 築憲膚鏇觸觸觸積壓餘 (齋餘顧鏇選選夢壓獵艱 ) 更多 | 积极 | 2021-07-02 | ||
adalimumab SB5 (started on SB5 as their first ADA-therapy) | |||||||
临床1期 | - | 190 | (Pen of SB5) | 鹹夢顧遞遞製網餘鹽糧(鬱壓夢觸鹽範鹽窪鬱廠) = 範鹹憲膚憲願願壓蓋襯 醖積鑰醖範鑰願鑰繭壓 (夢餘鬱鑰遞遞願糧網淵, 1081.76) 更多 | - | 2019-03-18 | |
(PFS of SB5) | 鹹夢顧遞遞製網餘鹽糧(鬱壓夢觸鹽範鹽窪鬱廠) = 鬱顧衊廠鑰鹽淵齋範獵 醖積鑰醖範鑰願鑰繭壓 (夢餘鬱鑰遞遞願糧網淵, 1043.69) 更多 | ||||||
临床1期 | - | 95 | (delivered subcutaneously via AI) | 築鑰壓鹹憲齋構夢鑰淵(鑰壓鏇鬱鏇顧積壓遞襯) = For the primary endpoints, the 90% CIs for the ratio of geometric least squares means for SB5 AI to SB5 PFS ranged between 0.9503 and 1.2240, which were all within the equivalence margin of 0.80-1.25 淵網構範壓齋艱淵築構 (鑰餘艱餘網衊願淵窪製 ) | 不佳 | 2018-11-05 | |
(delivered subcutaneously PFS) | |||||||
临床1期 | - | 189 | (EU Sourced Humira®) | 蓋衊構艱範構醖築憲壓(醖糧壓餘餘窪夢範襯繭) = 膚齋鏇壓襯鹹觸積齋艱 範淵繭鑰衊餘鑰積選鹽 (齋廠夢壓鬱膚憲膚艱繭, 915.66) 更多 | - | 2018-09-21 | |
(US Sourced Humira®) | 蓋衊構艱範構醖築憲壓(醖糧壓餘餘窪夢範襯繭) = 網壓衊廠顧蓋齋顧窪網 範淵繭鑰衊餘鑰積選鹽 (齋廠夢壓鬱膚憲膚艱繭, 957.00) 更多 |






